Merck & Co. has agreed to acquire biotechnology firm Cidara Therapeutics in a $9.2 billion deal, accelerating efforts to broaden its respiratory portfolio as it prepares for the loss of exclusivity on ...
KNOXVILLE, TN, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated response, safety, and immune correlative data from the Company’s ongoing Phase 1b clinical trial ...
Merck is kicking its Keytruda-related clash with Johns Hopkins University (JHU) up a notch by asking the U.S. Patent and Trademark Office (PTO) to weigh in following a 2022 complaint. The drugmaker ...
Merck Looks Well Positioned in the Near Term, but 2028 Keytruda Patent Loss Weighs on Long-Term View
Merck’s MRK combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...
Oct 16 (Reuters) - The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's (MRK.N), opens new tab blockbuster immunotherapy Keytruda in early-stage patients with ...
Drugmaker Merck & Co avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, ...
Merck’s cancer star Keytruda could be on its way to an updated label in HER2-positive stomach cancer after showing it can stave off tumor progression in a combination study. Keytruda scored its ...
The Food and Drug Administration granted Merck a priority review for its application for Keytruda in combination with concurrent chemoradiotherapy, the company announced Wednesday. According to Merck, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback